Skip to content

Adherence to Secondary Prevention Guidelines for Cardiovascular Risk

Adherence to Secondary Prevention Guidelines for Cardiovascular Risk

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06450561
Enrollment
129
Registered
2024-06-10
Start date
2024-03-01
Completion date
2025-09-30
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Atherosclerosis, Ischemic Heart Disease, Peripheral Arterial Disease, Stroke, Ischemic

Brief summary

The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.

Interventions

OTHERcardiovascular event

In this single group observational trial the exposure of interest is a cardiovascular event.

Sponsors

Consorci Sanitari de l'Alt Penedès i Garraf
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to the cardiology, neurology, or general surgery departments * With any of the following admission diagnoses: Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause

Exclusion criteria

* Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy * Patients likely to die during hospitalization * Patients who died during hospitalization

Design outcomes

Primary

MeasureTime frameDescription
patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at dischargeUp to 3 monthsProportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026